In this study the single session of small-volume (31) direct hemoperfusion (DHP) through uncoated (I group, 24 patients) and DNA-coated (II group, 17 patients) synthetic activated carbons has been investigated as an additive to the traditional medicamental treatment (III group, 22 patients) of the endogenous bronchial asthma. Significant amelioration of the main clinical and immunological indices in the patients of the I and II group in comparison with those of III group was noted. Between two DHP-including treatment modalities hemoimmunosorption onto DNA-coated activated charcoal is suggested as better.